About The Study: Among patients with Tourette syndrome, ecopipam, a selective dopamine D1 receptor antagonist, maintained tic suppression and was well tolerated for up to 24 weeks, without clinically significant metabolic or movement disorder adverse effects.
Corresponding Author: To contact the corresponding author, Donald L. Gilbert, MD, MS, email donald.gilbert@cchmc.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2026.1431)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1431?guestAccessKey=c85179fe-77e7-42fe-943f-751d1bee8c12&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626
JAMA Neurology